ResMed Inc. vs Sezzle Inc — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Sezzle Inc trades at $127.79 (market cap $3.95B). The key difference: ResMed Inc. is far larger — about 8.1× Sezzle Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Sezzle Inc for 15 Days on average.
| RMD | SEZL | |
|---|---|---|
Market Cap | $31.89B | $3.95B |
Volume | 618,314 | 550,075 |
Sector | Health | Financials |
52-Week High | $277.88 | $188.55 |
52-Week Low | $182.82 | $50.97 |
Typical Hold Time | 51 Days | 15 Days |
Enterprise Value | $31.24B | $3.99B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
SEZL stock trades at $126.61, up 11.21% with strong bullish momentum. The company demonstrates exceptional profitability with 30.35% net income margin and 88.85% ROE, supported by 51.7% revenue growth in Q2 2026. Technical indicators show bullish signals with current price above key support levels, while analyst consensus targets $168.00 representing 32.7% upside potential. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents compelling growth prospects with robust fundamentals and positive analyst sentiment, though elevated valuation multiples and competitive BNPL market dynamics warrant monitoring. The stock's current technical strength combined with strong earnings beats and institutional accumulation supports continued upside potential, while investors should consider the stock's premium valuation relative to historical norms.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →